Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

• Published in: Journal of autoimmunity Vol. 111; p. 102452
• Main Authors: Liu, Bingwen, Li, Min, Zhou, Zhiguang, Guan, Xuan, Xiang, Yufei
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.07.2020
• Subjects: Anti-Inflammatory Agents - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Betacoronavirus - pathogenicity; Coronavirus disease 2019; Coronavirus Infections - pathology; COVID-19; Cytokine release syndrome; Cytokine Release Syndrome - therapy; Humans; Immunomodulation - drug effects; Interleukin-6; Interleukin-6 - antagonists & inhibitors; Interleukin-6 - blood; Pandemics; Pneumonia, Viral - pathology; SARS-CoV-2; Severe Acute Respiratory Syndrome - pathology; Tocilizumab; Cytokine release syndrome; Coronavirus disease 2019; Tocilizumab; Interleukin-6

The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine...